Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of “Hold” by Brokerages

Posted by on Jul 26th, 2026

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) has been assigned an average recommendation of “Hold” from the four research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $14.50.

Several research firms have issued reports on VRCA. Zacks Research upgraded shares of Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. HC Wainwright began coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They set a “buy” rating and a $12.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, July 15th. Finally, Wall Street Zen cut Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday.

Get Our Latest Stock Report on Verrica Pharmaceuticals

Institutional Investors Weigh In On Verrica Pharmaceuticals

Several large investors have recently modified their holdings of VRCA. Affinity Asset Advisors LLC purchased a new position in shares of Verrica Pharmaceuticals during the fourth quarter worth approximately $5,878,000. Armistice Capital LLC boosted its stake in Verrica Pharmaceuticals by 75.1% during the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock worth $9,298,000 after purchasing an additional 479,732 shares during the period. Velan Capital Investment Management LP acquired a new stake in Verrica Pharmaceuticals during the 4th quarter worth $3,919,000. Boothbay Fund Management LLC purchased a new position in Verrica Pharmaceuticals during the 3rd quarter worth $1,210,000. Finally, Kalehua Capital Management LLC purchased a new position in Verrica Pharmaceuticals during the 4th quarter worth $1,959,000. 42.45% of the stock is owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Stock Down 7.7%

Shares of NASDAQ:VRCA opened at $5.02 on Friday. The company has a market capitalization of $86.24 million, a PE ratio of -4.87 and a beta of 1.47. The company has a current ratio of 2.10, a quick ratio of 1.98 and a debt-to-equity ratio of 0.03. Verrica Pharmaceuticals has a twelve month low of $3.28 and a twelve month high of $9.82. The firm has a 50 day simple moving average of $5.92 and a 200-day simple moving average of $6.24.

Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18. Verrica Pharmaceuticals had a negative net margin of 47.97% and a negative return on equity of 1,077.78%. The firm had revenue of $5.02 million for the quarter, compared to the consensus estimate of $4.51 million. On average, equities analysts predict that Verrica Pharmaceuticals will post -1.84 EPS for the current fiscal year.

Verrica Pharmaceuticals Company Profile

(Get Free Report)

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.

Further Reading

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.